Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeEXPOGLIONCT07788430
Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study
A study testing Biological sample collection and Self-reported questionnaire in people with Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, run by Institut Claudius Regaud at 1 site in France.
Trial summary
This prospective, interventional, monocentric study will aim at investigating the relationship between pesticide exposure and the treatment response of patients with GBM. The study will be conducted on a population of 120 participants aged over 18 years, diagnosed with IDH wild-type GBM, and who will receive the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- What is being tested?
- Biological sample collection and Self-reported questionnaire
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteFrance
- Study dates
- 15 Oct 2026to 15 Oct 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Patient newly diagnosed with IDH wild-type GBM
- 2. Age >18 years old at the time of study entry
- 3. Patient who have not yet started the treatment for GBM (by, where applicable, concomitant radiochemotherapy or chemotherapy in combination with targeted therapy)
- 4. Patient having signed an informed consent form prior to any study-related procedures
- 5. Patient able to participate and willing to comply with the study procedures
- 6. Patient affiliated to a Social Health Insurance in France
Who cannot join
- 1. Any condition contra-indicating sampling procedures required by the protocol.
- 2. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- 3. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, 31059
Adèle MEOLA, MD, +33(0) 5 31 15 51 21, meola.adele@iuct-oncopole.fr
Elizabeth COHEN-JONATHAN MOYAL, MD, PhD, +33 5 31 15 54 45, moyal.elizabeth@iuct-oncopole.fr
About this study
This prospective, interventional, monocentric study will aim at investigating the relationship between pesticide exposure and the treatment response of patients with GBM.
The study will be conducted on a population of 120 participants aged over 18 years, diagnosed with IDH wild-type GBM, and who will receive the treatment for GBM (by, where applicable, concomitant radiochemotherapy or chemotherapy in combination with targeted therapy).
Read more
The recruitment period will last 2 years. After eligibility is confirmed, study assessments will be performed at the baseline visit (i.e. before GBM treatment initiation). The study specific assessments consist of: biological sample collection (urine, hair and blood) and completion of a self-reported questionnaire.
The questionnaire will entail 2 parts: i- the main part delivered to all participants, ii- an optional part delivered only when a professional pesticide exposure is suspected (based on answers provided in part 1).
Then, the patient will be followed up for about 3 years (or 6 timepoints) for data collection. During this period, data collection will take place twice a year according to the routine visits at the investigator site for clinical benefit assessment to document tumor response, survival status and further anti-cancer treatments if applicable. This data is routinely captured in patient's medical records per SOC and will not require study specific visits.
The follow-up period might differ between patients as it will depend on the routine visit schedule. This schedule will be set up for each patient specifically according to their SOC.
Read the detailed description
The study assessments entail: biological sample collection and self-reported questionnaire completion.
- After the biological sample (urine and hair) collection, samples will be transfered to the Limoges Hospital for analysis (detection of pesticides residus and metabolites).
- After the optional blood sample collection, samples will be processed (Peripheral Blood Mononuclear Cell isolation) and stored at the sponsor site for constitution of a biobank (plasma and PBMC).
- The data pertaining to the self-reported questionnaires will be transfered to the INSERM team in Bordeaux for epidemiology analysis. The resulting Pesticides Exposure Scores will be integrated in the clinical database. No patient confidential information will be retained by the sub-contracting INSERM team after the end of the study.
- Being tested
- Biological sample collection, Self-reported questionnaire
- Keywords
- Glioblastoma, IDH wild-type, Pesticide exposure, Environmental risk factors
- Medical subject headings
- Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biological sample collectionOther
At the baseline visit, the following biological sample collection will be carried out:
- Urine sample (15 mL)
- Hair sample (50 to 100 hairs)
- Optional blood sample (40 mL)
Self-reported questionnaireOther
At the baseline visit, the patient will be handed a blank copy of the questionnaire to be completed at home. The patient will be asked to return the completed questionnaire within 1 month. Within two weeks of receipt, a member of the investigator staff will review the questionnaire for completeness and consistency and if necessary will make a follow-up phone call to the patient for clarification. If, based on the patient answers, a suspicion of occupational pesticide exposure is identified, the patient will be provided with a second part of the questionnaire in order to enhance the granularity of the answers. The patient will be given one month to return the questionnaire part 2 to the site staff. Within two weeks of receipt of the second part of the questionnaire, a member of the investigator staff will review it and contact the patient if necessary (see questionnaire part 1) The questionnaire part 1 should take about 1h and the part 2 about 30 minutes to fill out.
| Study group | Role | What they receive |
|---|---|---|
| Study assessments | Experimental | The same study assessments will apply to all study participants Receives: Other: Biological sample collection; Other: Self-reported questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival (PFS)
PFS is defined as the time from inclusion until progression (according to the investigator's judgment) or death. Patients alive without documented progression at last-follow-up news will be censored at this date.
Measured: through study completion, an average of 5 years
Pesticide Exposure
A patient is considered as exposed to pesticides if he meets at least one of the two following conditions:
- probability of professional exposure > 90% in at least one occupation
- environmental exposure
Measured: through study completion, an average of 5 years
Secondary outcomes (2)
Overall Survival (OS)
OS is defined as the time from inclusion to death from any cause. At the time of analysis, patients alive will be censored at the date of last follow-up news.
Measured: through study completion, an average of 5 years
Pesticide Exposure
Exposure to pesticides will be defined using the self-reported standardized questionnaire (derived from CERENAT study). Three types of exposition will be defined (professional, environmental and domestic) and different metrics will be derived from the questionnaire (probability, intensity…).
Measured: through study completion, an average of 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2026
- Study start15 Oct 2026 (estimated)
- Primary completion15 Oct 2031 (estimated)
- Study completion15 Oct 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Claudius Regaud
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07788430
- Sponsor's protocol ID
- 26 TETE 02
- Acronym
- EXPOGLIO
- Status last verified
- Aug 2026
- First submitted
- 20 Aug 2026
- Last updated
- 26 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study
- ClinicalTrials.gov ID
- NCT07788430
- Acronym / sponsor ID
- EXPOGLIO / 26 TETE 02
- Keywords
- Glioblastoma, IDH wild-type, Pesticide exposure, Environmental risk factors
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Institut Claudius RegaudUniversity, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France
- Study start
- 15 Oct 2026 (estimated)
- Primary completion
- 15 Oct 2031 (estimated)
- Study completion
- 15 Oct 2031 (estimated)
- First posted
- 26 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, interventional, monocentric study will aim at investigating the relationship between pesticide exposure and the treatment response of patients with GBM.
The study will be conducted on a population of 120 participants aged over 18 years, diagnosed with IDH wild-type GBM, and who will receive the treatment for GBM (by, where applicable, concomitant radiochemotherapy or chemotherapy in combination with targeted therapy).
The recruitment period will last 2 years. After eligibility is confirmed, study assessments will be performed at the baseline visit (i.e. before GBM treatment initiation). The study specific assessments consist of: biological sample collection (urine, hair and blood) and completion of a self-reported questionnaire.
The questionnaire will entail 2 parts: i- the main part delivered to all participants, ii- an optional part delivered only when a professional pesticide exposure is suspected (based on answers provided in part 1).
Then, the patient will be followed up for about 3 years (or 6 timepoints) for data collection. During this period, data collection will take place twice a year according to the routine visits at the investigator site for clinical benefit assessment to document tumor response, survival status and further anti-cancer treatments if applicable. This data is routinely captured in patient's medical records per SOC and will not require study specific visits.
The follow-up period might differ between patients as it will depend on the routine visit schedule. This schedule will be set up for each patient specifically according to their SOC.
Detailed description
The study assessments entail: biological sample collection and self-reported questionnaire completion.
- After the biological sample (urine and hair) collection, samples will be transfered to the Limoges Hospital for analysis (detection of pesticides residus and metabolites).
- After the optional blood sample collection, samples will be processed (Peripheral Blood Mononuclear Cell isolation) and stored at the sponsor site for constitution of a biobank (plasma and PBMC).
- The data pertaining to the self-reported questionnaires will be transfered to the INSERM team in Bordeaux for epidemiology analysis. The resulting Pesticides Exposure Scores will be integrated in the clinical database. No patient confidential information will be retained by the sub-contracting INSERM team after the end of the study.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study assessments | Experimental | Other: Biological sample collection, Other: Self-reported questionnaireThe same study assessments will apply to all study participants |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 1. Patient newly diagnosed with IDH wild-type GBM
- 2. Age >18 years old at the time of study entry
- 3. Patient who have not yet started the treatment for GBM (by, where applicable, concomitant radiochemotherapy or chemotherapy in combination with targeted therapy)
- 4. Patient having signed an informed consent form prior to any study-related procedures
- 5. Patient able to participate and willing to comply with the study procedures
Key exclusion criteria (3 listed)
- 1. Any condition contra-indicating sampling procedures required by the protocol.
- 2. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- 3. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biological sample collectionAt the baseline visit, the following biological sample collection will be carried out: * Urine sample (15 mL) * Hair sample (50 to 100 hairs) * Optional blood sample (40 mL) | Other | Study assessments |
| Self-reported questionnaireAt the baseline visit, the patient will be handed a blank copy of the questionnaire to be completed at home. The patient will be asked to return the completed questionnaire within 1 month. Within two weeks of receipt, a member of the investigator staff will review the questionnaire for completeness and consistency and if necessary will make a follow-up phone call to the patient for clarification. If, based on the patient answers, a suspicion of occupational pesticide exposure is identified, the patient will be provided with a second part of the questionnaire in order to enhance the granularity of the answers. The patient will be given one month to return the questionnaire part 2 to the site staff. Within two weeks of receipt of the second part of the questionnaire, a member of the investigator staff will review it and contact the patient if necessary (see questionnaire part 1) The questionnaire part 1 should take about 1h and the part 2 about 30 minutes to fill out. | Other | Study assessments |
Primary outcome
Progression-Free Survival (PFS)
Time frame: through study completion, an average of 5 years
PFS is defined as the time from inclusion until progression (according to the investigator's judgment) or death. Patients alive without documented progression at last-follow-up news will be censored at this date.
Pesticide Exposure
Time frame: through study completion, an average of 5 years
A patient is considered as exposed to pesticides if he meets at least one of the two following conditions: * probability of professional exposure > 90% in at least one occupation * environmental exposure
2 secondary outcomes
Overall Survival (OS)
Time frame: through study completion, an average of 5 years
Pesticide Exposure
Time frame: through study completion, an average of 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
Related trials for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
RecruitingPhase 2/3
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma
RecruitingPhase 1/2
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Not yet recruitingPhase 2
Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas
Glioblastoma, Glioblastoma, IDH-wildtype
RecruitingPhase 1/2
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Not yet recruitingPhase 2
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Biological sample collection and Self-reported questionnaire in people with Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, run by Institut Claudius Regaud at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Adèle MEOLA, MD (+33(0) 5 31 15 51 21, meola.adele@iuct-oncopole.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival (PFS) (time frame: through study completion, an average of 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.